Latest Regulatory Filings News

Identitii lifted annual recurring revenue 21% to $865,000 and expanded its sales pipeline 70% during the September quarter as new transaction-monitoring tools went live. But the fintech ended the period with negative cash of $44,000, leaving its near-term funding position dependent on further convertible-note proceeds and improved operating cash flow.

Alterity Therapeutics says it has begun operational preparations for a Phase 3 ATH434 trial after FDA minutes confirmed the proposed design and registrational pathway in Multiple System Atrophy. The company ended September with A$41.3 million in cash, while a new US patent extends protection for ATH434 to 2045.

Sequoia Financial Group reported a sharp first-quarter revenue decline and pretax loss as authorised representatives left its InterPrac licence. Cash rose to A$11.4 million, but the balance was bolstered by the sale of Centrepoint Alliance shares while ASIC continues to question documentation linked to the InterPrac exit.

Great Divide Mining increased Challenger concentrate production and plant feed rates during the September quarter, but ended with A$433,000 in cash and an estimated 0.9 quarters of funding. The company is relying on higher production, cost control or potential equity funding while advancing Coonambula towards a maiden resource estimate.

Dome Gold Mines has reached a regulatory milestone at its Sigatoka heavy mineral sands project, but remains suspended from trading with no cash on hand and its annual audit unfinished. The company is seeking up to A$3 million through convertible notes while it negotiates funding for valuation work and working capital.

Arafura Rare Earths has moved its Nolans rare earths project from financing decision to early construction, with A$700 million of procurement scope advanced during the September quarter. The company ended the period with A$885 million in cash and term deposits, while major debt and equity funding arrangements remain subject to completion conditions.

Rapid Critical Metals reported expanding high-grade silver mineralisation at Webbs and strong processing test results, but ended September with $3.548 million in cash against quarterly relevant outgoings of $3.824 million. The company said it has not yet started a funding process, although it expects to consider its options.

Taruga Minerals has mobilised its first diamond drill rig at the Weioko Gold Deposit since 2009, while preliminary oxide testwork returned gold recoveries of up to 96.27%. The results are encouraging, but the company’s cash position remains tight before a post-quarter option exercise raised A$1.5 million.

Pivotal Metals has put a A$920 million post-tax NPV on its Horden Lake copper project, while continued drilling and target generation broaden the company’s Quebec growth story. The attraction comes with familiar development-stage caveats: the study is preliminary, includes inferred material and leaves Pivotal with about 2.4 quarters of funding at the reported spending rate.

Paradigm Biopharmaceuticals’ pivotal knee osteoarthritis trial fell below its pre-specified continuation threshold, leaving the ASX-listed biotech in voluntary administration with A$4.33 million in cash. Administrators now have up to three months to assess restructuring options, clinical data and the company’s future.

Middle Island Resources has connected three mineralised zones at its Bobija project in Serbia into an 80,000-square-metre shallow polymetallic system, while confirming sizeable copper and gold targets elsewhere in its portfolio. The explorer is also shedding its Northern Territory licences to reduce annual commitments by about $400,000, but reported only $1.694 million in quarter-end cash.

Caravel Minerals has completed the mining component of its Caravel Copper Project feasibility study, but the full DFS has slipped into the fourth quarter of 2026. The company is also reviewing process plant costs while holding $16.8 million in cash and reporting an estimated 4.6 quarters of funding at the quarter’s outflow rate.